Compare ARQT & ATRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQT | ATRO |
|---|---|---|
| Founded | 2016 | 1968 |
| Country | United States | United States |
| Employees | N/A | 2700 |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2020 | N/A |
| Metric | ARQT | ATRO |
|---|---|---|
| Price | $28.05 | $68.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $34.00 | ★ $86.00 |
| AVG Volume (30 Days) | ★ 1.7M | 780.3K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $376,072,000.00 | N/A |
| Revenue This Year | $34.85 | $14.92 |
| Revenue Next Year | $29.39 | $8.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 91.34 | N/A |
| 52 Week Low | $13.70 | $27.27 |
| 52 Week High | $31.77 | $99.89 |
| Indicator | ARQT | ATRO |
|---|---|---|
| Relative Strength Index (RSI) | 61.54 | 38.08 |
| Support Level | $27.63 | $62.03 |
| Resistance Level | $29.91 | $79.86 |
| Average True Range (ATR) | 1.20 | 3.92 |
| MACD | -0.06 | -0.77 |
| Stochastic Oscillator | 62.20 | 17.64 |
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Astronics Corporation is a provider of technologies to the aerospace, defense, and electronics industries, offering high-performance electrical power generation and distribution systems, motion systems, lighting and safety systems, avionics products, systems certification, aircraft structures, and automated test systems. The company operates through two reportable segments, Aerospace and Test Systems. The Aerospace segment designs and manufactures products for the aerospace and defense industry and generates the majority of revenue, while the Test Systems segment designs, develops, manufactures, and maintains automated test systems for the aerospace and defense, communications, and mass transit industries. The company derives the majority of its revenue from the United States.